ArticleCancer research and treatment2026

Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13).

Jwa Hoon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.